Company intelligence / Profile preview

Primagen

Amsterdam, North Holland, Netherlands

Ownership: Private
Development stage: Other

Overview

Primagen was a Dutch biotechnology company specializing in the development and commercialization of molecular diagnostic tests for infectious diseases. The company leveraged its proprietary Nucleic Acid Sequence Based Amplification (NASBA) technology to provide sensitive and specific quantitative assays for monitoring viral loads in patients with HIV, Hepatitis C, and other viral infections. Primagen's products were designed to improve clinical decision-making by providing rapid and accurate molecular insights. In 2005, the company was acquired by bioMérieux to strengthen its molecular diagnostics portfolio.

Therapeutic areas: Infectious Diseases
Modalities: Molecular diagnosticsNucleic acid amplification
Industry: Molecular Diagnostics

Partnerships

bioMérieux

Beyond the preview

Go deeper on Primagen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Primagen.

Explore the full profile